StockData

Surrozen vs Voyager Therapeutics

SRZN and VYGR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How SRZN and VYGR compare

Surrozen is the larger company, worth 3.8 times as much as Voyager Therapeutics ($352M against $93.7M).

Surrozen grew revenue faster over the last twelve months (−8.8% versus −19.1% for Voyager Therapeutics).

Voyager Therapeutics keeps more of each dollar of sales as profit, with a net margin of −313% compared with −2885% at Surrozen.

Voyager Therapeutics scores higher on the StockData Score (9 against 5 for Surrozen), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricSRZNVYGR
Size and price
Market cap$352M$93.7M
Share price$29.98$1.52
Change, 1 year131%−61.3%
Change, 5 years−77.8%−50.3%
Beta (5Y)1.881.21
Employees44141
StockData Score
Total score59 (better)
Valuation score03 (better)
Growth score00
Performance score01 (better)
Health score55
Dividend score00
Valuation
P/S30.6×2.7× (better)
P/B–0.6×
FCF yield−9.9% (better)−130%
Fair value–$3.59
Margin of safety–57.6%
Growth
Revenue growth (TTM)−8.8% (better)−19.1%
Revenue growth, 5Y average–−25.1%
Profitability
Operating margin−385%−340% (better)
Net margin−2885%−313% (better)
FCF margin−304% (better)−352%
Return on equity–−54.1%
Financial health
Debt / equity–0.00
Current ratio12.14 (better)7.51
Altman Z-score−6.81−3.35 (better)
Piotroski F-score3 (better)2
Dividends and buybacks
Buyback yield−0.99%–
Shareholder yield−0.99%0.00% (better)
Ownership
Held by institutions91.3%56.9%
Held by insiders44.5%2.6%
Insider net buying, 12 months$1.6M (better)−$298K
Short interest, % of float49.6%7.3%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.